Single Biggest Cancer Dictionary in the World

What is threonine tyrosine kinase inhibitor CFI-402257?

Pronunciation: /threonine* tyrosine* kinase* ˌɪnˈhɪbətər cfi* fɔr ˈhənərd ənd tu ˈθaʊzənd, tu ˈhənərd ənd fifty-seven*/

threonine tyrosine kinase inhibitor CFI-402257

Definition

An orally bioavailable, selective inhibitor of the dual specificity protein kinase TTK (monopolar spindle 1 kinase, Mps1), with potential antineoplastic activity. Upon administration, luvixasertib selectively binds to and inhibits the activity of Mps1. This inactivates the spindle assembly checkpoint (SAC) and accelerates mitosis, which results in chromosomal misalignment and missegregation, and mitotic checkpoint complex destabilization. This induces cell death in Mps1-overexpressing cancer cells. Mps1, a tyrosine and serine/threonine kinase expressed in proliferating normal tissues, is essential for proper SAC functioning and chromosome alignment. Overexpressed in various human tumors, Mps1 plays a key role in uncontrolled tumor cell growth.